{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T07:52:16Z","timestamp":1766908336828,"version":"3.37.3"},"reference-count":26,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T00:00:00Z","timestamp":1514332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100013130","name":"Mundipharma Korea Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013130","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>To investigate the efficacy and safety of oxycodone\/naloxone in patients with chemotherapy\u2010induced peripheral neuropathy (CIPN) inadequately controlled with pregabalin or gabapentin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This 4\u2010week, multicenter, interventional, single\u2010arm phase IV study included 72 Korean patients with CIPN inadequately controlled with pregabalin or gabapentin (Numeric Rating Scale 0\u201310; NRS \u22654 at baseline). In addition to pregabalin or gabapentin at existing doses, patients received 20\/10 mg\/day oxycodone\/naloxone (up\u2010titrated to 80\/40 mg\/day as needed). The primary endpoint was change in NRS score after 4 weeks. Secondary endpoints included Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group\u2010Neurotoxicity (FACT\/GOG\u2010NTX) scores and safety assessments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mean \u00b1 standard deviation (SD) dose of oxycodone\/naloxone was 23.3\u00a0\u00b1\u00a07.5 mg\/day. At week 4, NRS score reduction was 1.29\u00a0\u00b1\u00a01.84 points (21.4% reduction; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.0001). Patients on taxane\u2010based chemotherapy experienced a significantly smaller mean change in NRS score at week 4 compared to patients on other chemotherapy (\u22120.63 \u00b1 1.54 [<jats:italic>n<\/jats:italic> = 30] vs. \u22121.83 \u00b1 1.00 [<jats:italic>n<\/jats:italic> = 36]; <jats:italic>P<\/jats:italic> = 0.0072). Although there were no significant changes in FACT\/GOG\u2010NTX total scores, improvements were observed in the neurotoxicity subscale measuring numbness\/tingling of hands (mean \u00b1\u00a0SD change: \u22120.27 \u00b1 1.04; <jats:italic>P<\/jats:italic> = 0.0427) and feet (\u22120.60 \u00b1 1.09; <jats:italic>P<\/jats:italic> &lt; 0.0001). Forty\u2010two (58.3%) patients reported adverse events. There were no clinically significant changes in laboratory tests or vital signs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Oxycodone\/naloxone added to pregabalin or gabapentin provided additional pain relief and symptom control in Korean patients with CIPN, without clinically significant safety concerns.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajco.12822","type":"journal-article","created":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T09:37:00Z","timestamp":1514367420000},"source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and safety of oxycodone\/naloxone as add\u2010on therapy to gabapentin or pregabalin for the management of chemotherapy\u2010induced peripheral neuropathy in Korea"],"prefix":"10.1111","volume":"14","author":[{"given":"Bong\u2010Seog","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Hemato\u2010Oncology VHS Medical Center  Seoul South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong\u2010Youl","family":"Jin","sequence":"additional","affiliation":[{"name":"Division of Hemato\u2010Oncology Bucheon St. Mary's Hospital The Catholic University of Korea  Bucheon South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Hye","family":"Kwon","sequence":"additional","affiliation":[{"name":"Division of Hemato\u2010Oncology Kangdong Sacred Heart Hospital Hallym University  Seoul South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In Sook","family":"Woo","sequence":"additional","affiliation":[{"name":"Yeouido St. Mary's Hospital College of Medicine The Catholic University of Korea  Seoul South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon Ho","family":"Ko","sequence":"additional","affiliation":[{"name":"Division of Oncology Uijeongbu St. Mary's Hospital The Catholic University of Korea  Uijeongbu South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suk\u2010Young","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Oncology Daejeon St. Mary's Hospital The Catholic University of Korea  Daejeon South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye\u2010Jeong","family":"Park","sequence":"additional","affiliation":[{"name":"Medical Affairs Mundipharma Korea Ltd.  Seoul South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3845-7260","authenticated-orcid":false,"given":"Jin Hyung","family":"Kang","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology Seoul St. Mary's Hospital The Catholic University of Korea  Seoul South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,12,27]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2014.09.020"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S44261"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2009.0078"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.0914"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2132-4"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1511-y"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1159\/000186502"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2007.12.010"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.866545"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0177-9"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-014-0026-2"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2003.13603.x"},{"key":"e_1_2_9_14_1","unstructured":"National Cancer Institute.Common Terminology Criteria for Adverse Events (CTCAE) v4.0.http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm. Accessed 25 May 2016."},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.12.010"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2005.12.010"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(01)00349-9"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2014.04.004"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6904-10-12"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2008.06.014"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269216311418869"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.4097\/kjae.2014.67.1.4"},{"key":"e_1_2_9_23_1","unstructured":"National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology: Adult Cancer Pain (version 1.2014).2014. Accessed 23 May 2016."},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.2813"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.2174\/157015906776359568"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8027.2011.00351.x"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8027.2010.00292.x"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajco.12822","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.12822","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T23:22:27Z","timestamp":1694992947000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.12822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,27]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1111\/ajco.12822"],"URL":"https:\/\/doi.org\/10.1111\/ajco.12822","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"type":"print","value":"1743-7555"},{"type":"electronic","value":"1743-7563"}],"subject":[],"published":{"date-parts":[[2017,12,27]]}}}